Interrogating open issues in cancer precision medicine with patient-derived xenografts

Annette T Byrne¹, Denis G Alférez², Frédéric Amant^{3

4}, Daniela Annibali³, Joaquín Arribas^{5

6}, Andrew V Biankin⁷, Alejandra Bruna⁸, Eva Budinská⁹, Carlos Caldas⁸, David K Chang⁷, Robert B Clarke², Hans Clevers¹⁰, George Coukos¹¹, Virginie Dangles-Marie¹², S Gail Eckhardt¹³, Eva Gonzalez-Suarez¹⁴, Els Hermans³, Manuel Hidalgo¹⁵, Monika A Jarzabek¹, Steven de Jong¹⁶, Jos Jonkers¹⁷, Kristel Kemper¹⁷, Luisa Lanfrancone¹⁸, Gunhild Mari Mælandsmo¹⁹, Elisabetta Marangoni²⁰, Jean-Christophe Marine²¹, Enzo Medico²², Jens Henrik Norum¹⁹, Héctor G Palmer²³, Daniel S Peeper¹⁷, Pier Giuseppe Pelicci¹⁸, Alejandro Piris-Gimenez²³, Sergio Roman-Roman²⁰, Oscar M Rueda⁸, Joan Seoane^{5

6}, Violeta Serra²³, Laura Soucek⁵, Dominique Vanhecke¹¹, Alberto Villanueva²⁴, Emilie Vinolo²⁵, Andrea Bertotti²², Livio Trusolino²²

Affiliations

¹ EurOPDX Consortium and are at the Royal College of Surgeons in Ireland, Dublin 2, Ireland.
² EurOPDX Consortium and are at the Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester M20 4QL, UK.
³ EurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
⁴ The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
⁵ EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology, 08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
⁶ CIBERONC, 08035 Barcelona, Spain.
⁷ EurOPDX Consortium and are at the Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
⁸ EurOPDX Consortium and are at Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, UK.
⁹ EurOPDX Consortium and is at the Institute of Biostatistics and Analyses, Faculty of Medicine, and Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masarykova Univerzita, 625 00 Brno, Czech Republic.
¹⁰ Hubrecht Institute, University Medical Centre Utrecht, and Princess Maxima Center for Pediatric Oncology, 3584CT Utrecht, The Netherlands.
¹¹ EurOPDX Consortium and are at Lausanne Branch, Ludwig Institute for Cancer Research at the University of Lausanne, 1066 Lausanne, Switzerland.
¹² EurOPDX Consortium and is at the Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, and Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie de Paris, 75006 Paris, France.
¹³ University of Colorado Cancer Center, Aurora, Colorado 80045, USA.
¹⁴ EurOPDX Consortium and is at the Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute IDIBELL, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
¹⁵ EurOPDX Consortium and is at Beth Israel Deaconess Medical Center, Boston, Harvard Medical School, Boston, Massachusetts 02215, USA.
¹⁶ EurOPDX Consortium and is at the University Medical Centre Groningen, University of Groningen, 9713GZ Groningen, The Netherlands.
¹⁷ EurOPDX Consortium and are at The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
¹⁸ EurOPDX Consortium and are at the Department of Experimental Oncology, European Institiute of Oncology, 20139 Milan, Italy.
¹⁹ EurOPDX Consortium and are at Oslo University Hospital, Institute for Cancer Research, 0424 Oslo, Norway.
²⁰ EurOPDX Consortium and are at Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, France.
²¹ EurOPDX Consortium and is at the Laboratory for Molecular Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, and the Center for Cancer Biology, VIB, 3000 Leuven, Belgium.
²² EurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
²³ EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology and CIBERONC, 08035 Barcelona, Spain.
²⁴ EurOPDX Consortium and is at the Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology ICO, Bellvitge Biomedical Research Institute IDIBELL, 08098 L'Hospitalet de Llobregat, Barcelona, and Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
²⁵ Seeding Science SAS, 75020 Paris, France.

PMID: 28104906
DOI: 10.1038/nrc.2016.140

Free article

Review

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Annette T Byrne et al. Nat Rev Cancer. 2017 Apr.

Free article

. 2017 Apr;17(4):254-268.

doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20.

Authors

Affiliations

¹ EurOPDX Consortium and are at the Royal College of Surgeons in Ireland, Dublin 2, Ireland.
² EurOPDX Consortium and are at the Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester M20 4QL, UK.
³ EurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
⁴ The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
⁵ EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology, 08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
⁶ CIBERONC, 08035 Barcelona, Spain.
⁷ EurOPDX Consortium and are at the Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
⁸ EurOPDX Consortium and are at Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, UK.
⁹ EurOPDX Consortium and is at the Institute of Biostatistics and Analyses, Faculty of Medicine, and Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masarykova Univerzita, 625 00 Brno, Czech Republic.
¹⁰ Hubrecht Institute, University Medical Centre Utrecht, and Princess Maxima Center for Pediatric Oncology, 3584CT Utrecht, The Netherlands.
¹¹ EurOPDX Consortium and are at Lausanne Branch, Ludwig Institute for Cancer Research at the University of Lausanne, 1066 Lausanne, Switzerland.
¹² EurOPDX Consortium and is at the Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, and Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie de Paris, 75006 Paris, France.
¹³ University of Colorado Cancer Center, Aurora, Colorado 80045, USA.
¹⁴ EurOPDX Consortium and is at the Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute IDIBELL, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
¹⁵ EurOPDX Consortium and is at Beth Israel Deaconess Medical Center, Boston, Harvard Medical School, Boston, Massachusetts 02215, USA.
¹⁶ EurOPDX Consortium and is at the University Medical Centre Groningen, University of Groningen, 9713GZ Groningen, The Netherlands.
¹⁷ EurOPDX Consortium and are at The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
¹⁸ EurOPDX Consortium and are at the Department of Experimental Oncology, European Institiute of Oncology, 20139 Milan, Italy.
¹⁹ EurOPDX Consortium and are at Oslo University Hospital, Institute for Cancer Research, 0424 Oslo, Norway.
²⁰ EurOPDX Consortium and are at Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, France.
²¹ EurOPDX Consortium and is at the Laboratory for Molecular Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, and the Center for Cancer Biology, VIB, 3000 Leuven, Belgium.
²² EurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
²³ EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology and CIBERONC, 08035 Barcelona, Spain.
²⁴ EurOPDX Consortium and is at the Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology ICO, Bellvitge Biomedical Research Institute IDIBELL, 08098 L'Hospitalet de Llobregat, Barcelona, and Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
²⁵ Seeding Science SAS, 75020 Paris, France.

PMID: 28104906
DOI: 10.1038/nrc.2016.140

Erratum in

Interrogating open issues in cancer medicine with patient-derived xenografts.
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Byrne AT, et al. Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. Online ahead of print. Nat Rev Cancer. 2017. PMID: 28912576

Abstract

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

PubMed Disclaimer

Cited by

Current status and perspectives of patient-derived rare cancer models.
Kondo T. Kondo T. Hum Cell. 2020 Oct;33(4):919-929. doi: 10.1007/s13577-020-00391-1. Epub 2020 Jun 14. Hum Cell. 2020. PMID: 32537685 Review.
Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
Castillo-Ecija H, Pascual-Pasto G, Perez-Jaume S, Resa-Pares C, Vila-Ubach M, Monterrubio C, Jimenez-Cabaco A, Baulenas-Farres M, Muñoz-Aznar O, Salvador N, Cuadrado-Vilanova M, Olaciregui NG, Balaguer-Lluna L, Burgueño V, Vicario FJ, Manzanares A, Castañeda A, Santa-Maria V, Cruz O, Celis V, Morales La Madrid A, Garraus M, Gorostegui M, Vancells M, Carrasco R, Krauel L, Torner F, Suñol M, Lavarino C, Mora J, Carcaboso AM. Castillo-Ecija H, et al. J Pathol Clin Res. 2021 Jul;7(4):338-349. doi: 10.1002/cjp2.210. Epub 2021 Apr 9. J Pathol Clin Res. 2021. PMID: 33837665 Free PMC article.
Patient-Derived Tumor Xenograft Models: Toward the Establishment of Precision Cancer Medicine.
Goto T. Goto T. J Pers Med. 2020 Jul 18;10(3):64. doi: 10.3390/jpm10030064. J Pers Med. 2020. PMID: 32708458 Free PMC article. Review.
Clinical trial design: Past, present, and future in the context of big data and precision medicine.
Li A, Bergan RC. Li A, et al. Cancer. 2020 Nov 15;126(22):4838-4846. doi: 10.1002/cncr.33205. Epub 2020 Sep 15. Cancer. 2020. PMID: 32931022 Free PMC article. Review.
Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling.
Tan X, Kong D, Tao Z, Cheng F, Zhang B, Wang Z, Mei Q, Chen C, Wu K. Tan X, et al. Biomark Res. 2024 Jan 25;12(1):13. doi: 10.1186/s40364-024-00558-0. Biomark Res. 2024. PMID: 38273343 Free PMC article.

See all "Cited by" articles

References

1. Clin Cancer Res. 2014 Aug 15;20(16):4251-61 - PubMed
1. Cancer Res. 2016 Oct 1;76(19):5798-5809 - PubMed
1. Nat Rev Drug Discov. 2013 Aug;12(8):569 - PubMed
1. Blood. 2011 Sep 22;118(12):3426-35 - PubMed
1. Oncogene. 2016 Jan 21;35(3):290-300 - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Affiliations

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Authors

Affiliations

Erratum in

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources